MORPHINE SULFATE (morphine sulfate) by ICU Medical is mu-opioid receptor, although it can bind to other opioid receptors at higher doses. First approved in 1992.
Drug data last refreshed 23h ago · AI intelligence enriched 1mo ago
Morphine sulfate is a mu-opioid receptor agonist indicated for pain management via injection. It provides analgesia without a ceiling effect, with dosing titrated to patient response and tolerability. The precise mechanism involves CNS opioid receptors in the brain and spinal cord.
As LOE approaches, brand team focus shifts from growth to lifecycle extension and generic containment strategies, likely with reduced headcount.
mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of morphine is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with morphine. Clinically, dosage is titrated to provide adequate analgesia and may…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo
Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR)
Worked on MORPHINE SULFATE at ICU Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on morphine sulfate offers foundational pharmaceutical experience in a stable, legacy product with established market presence, but limited growth upside and innovation. Careers here pivot toward operational excellence, cost containment, and generic defense rather than pipeline expansion.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo